Core Insights - The social security fund has disclosed its stock holdings for the third quarter, appearing in the top ten circulating shareholders of 20 stocks, with 9 new entries and 4 increases in holdings [1][2] Group 1: Stock Holdings - The total number of shares held by the social security fund in the 20 stocks is 68.2952 million, with a total market value of 4.237 billion yuan [1] - New entries include Sanyou Medical, Dongwei Technology, and Lexin Technology, with significant holdings [1] - The stocks with the highest number of social security fund shareholders include Yingxi Network, Nanwei Medical, Zhongwang Software, and Zhuoyi Information, with holdings of 7.934 million, 6.269 million, 3.809 million, and 2.337 million shares respectively [1] Group 2: Shareholding Ratios - The stock with the highest shareholding ratio by the social security fund is Haitai Xinguang, at 4.20%, followed by Nanwei Medical at 3.34% [2] - The largest number of shares held is in Yingxi Network, with 7.934 million shares, followed closely by Sanyou Medical and Nanwei Medical with 7.9145 million and 6.2692 million shares respectively [2] - The stocks with the highest market value held by the social security fund include Nanwei Medical, Lexin Technology, and Bochu Electronics, valued at 629 million, 598 million, and 542 million yuan respectively [2] Group 3: Performance Metrics - Among the stocks held by the social security fund, 15 reported year-on-year net profit growth in the first three quarters, with Sanyou Medical showing the highest increase of 623.19% [2] - Other notable net profit growth includes Shen Gong Co. and Xinxiang Micro, with increases of 158.93% and 138.88% respectively [2] - The social security fund's holdings are primarily concentrated in the electronics, computer, and power equipment industries, with 5, 4, and 3 stocks respectively [2] Group 4: Market Performance - The average decline of the stocks held by the social security fund since October is 3.32% [3] - The best-performing stock is Puyuan Precision, with a cumulative increase of 6.18%, followed by Maide Medical and Yingshi Innovation with increases of 4.89% and 4.22% respectively [3] - The stock with the largest decline is Lexin Technology, which has dropped by 13.80% [3]

Group 1 - The core point of the news is the performance and changes in the top holdings of the招商信用增强债券型基金, which reported a net value growth rate of 7.78% over the past year [1] - The fund's top ten holdings saw the addition of new stocks including 海康威视, 中国国航, 东方钽业, 佰维存储, 航亚科技, 华鲁恒升, and 漫步者 [1] - 盛达资源 became the fund's largest holding with an increase of 137.4 million shares, while several stocks like 赛轮轮胎 and 国联股份 exited the top ten holdings [1] Group 2 - The detailed data of the top holdings includes the number of shares held and their market value, with 海康威视 holding 199.49 thousand shares valued at 0.63 billion, and 盛达资源 holding 277.37 thousand shares valued at 0.73 billion [1] - The fund's strategy reflects a significant increase in positions for stocks like 盛达资源 and 卫星化学, with increases of 98.16% and 103.52% respectively [1] - The report indicates a shift in investment focus, as several previous top holdings have been removed from the list, suggesting a reallocation of assets [1]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% against the benchmark index in the next 6 to 12 months [9] Core Views - The company is experiencing stable revenue in the domestic market while rapidly expanding in overseas markets, leveraging competitive sales channels and brand promotion [6][8] - The company is focusing its R&D resources on key project development, which is expected to enhance the performance of its 3D CAD products significantly [6][8] - The company has adjusted its revenue and profit forecasts for 2025-2027 due to macroeconomic pressures, projecting revenues of 9.63 billion, 10.96 billion, and 12.63 billion respectively, and net profits of 0.86 billion, 1.23 billion, and 1.69 billion [6][8] Financial Summary - For 2023, the company achieved a revenue of 828 million, with a year-on-year growth rate of 38%, and a net profit of 61 million, reflecting a significant growth of 874% [2][6] - The projected earnings per share (EPS) for 2025 is 0.51, with a net profit margin expected to increase to 13.3% by 2027 [2][8] - The company’s market capitalization is approximately 13.42 billion, with a current share price of 79.16 [3][6]

以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 2025年10月25日，中望软件(688083.SH)发布2025年第三季报。截至2025年10月24日，共有7个机构投资 者披露持有中望软件A股股份，合计持股量达1647.54万股，占中望软件总股本的9.72%。其中，机构投 资者包括交通银行股份有限公司-万家行业优选混合型证券投资基金(LOF)、招商银行股份有限公司-兴 全合润混合型证券投资基金、中国工商银行股份有限公司-万家自主创新混合型证券投资基金、全国社 保基金一一零组合、全国社保基金一一四组合、南方基金优选成长股票型养老金产品-招商银行股份有 限公司、广东毅达创新创业投资合伙企业(有限合伙)，机构投资者合计持股比例达9.72%。相较于上一 季度，机构持股比例合计下跌了3.73个百分点。 公募基金方面本期较上一季度持股减少的公募基金共计1个，即万家自主创新混合A，持股减少占比达 0.29%。本期较上一季未再披露的公募基金共计205个，主要包括万家经济新动能混合A、东方红新动力 混合A、兴全合宜混合A、东方红智华三年持有混合A、南方中证1000ETF等。 ...

Core Viewpoint - The company reported stable revenue and significant profit growth in the third quarter, focusing on long-term value creation and strategic partnerships in both domestic and international markets [2][3]. Financial Performance - The company achieved a total operating revenue of 204.26 million yuan, remaining stable compared to the same period last year [2]. - The net profit attributable to shareholders was 11.56 million yuan, representing a 141.18% increase year-on-year [3]. Business Strategy - The company is actively exploring new business opportunities arising from policy support and the transformation of the manufacturing industry, while maintaining strategic collaborations with industry leaders [2]. - In the international market, the company continues to experience rapid growth, leveraging competitive sales channels and enhanced brand promotion [2]. Research and Development - The company is committed to long-term value creation, focusing on key project development and enhancing the performance of its 3D CAD products [3]. - The official release of ZWCAD 365 has improved the 2D CAD product matrix and met the collaborative design needs of key clients [3]. Shareholder Information - The company announced the approval of the second vesting period for its 2023 restricted stock incentive plan, with 154,868 shares eligible for vesting [31][43]. - A total of 36,744 shares were canceled due to non-fulfillment of vesting conditions by certain employees [24][26]. Governance Changes - The company has made adjustments to its board committees, including the appointment of a new member to the remuneration and assessment committee [51][52].

Core Insights - Zhongwang Software reported a revenue of 204 million yuan for Q3 2025, reflecting a year-on-year growth of 0.08% [1] - The net profit for Q3 2025 was 11.56 million yuan, showing a significant year-on-year increase of 141.18% [1] - For the first three quarters of 2025, Zhongwang Software achieved a total revenue of 538 million yuan, which is a year-on-year growth of 4.99%, but reported a net loss of 51.98 million yuan [1]

Core Insights - Zhongwang Software (688083.SH) reported a third-quarter revenue of 204 million yuan, reflecting a year-on-year growth of 0.08% [1] - The net profit attributable to shareholders reached 11.5572 million yuan, marking a significant year-on-year increase of 141.18% [1] - The basic earnings per share stood at 0.07 yuan [1]

Group 1 - The core point of the article is that Zhongwang Software (SH 688083) held its 20th meeting of the 6th board of directors on October 24, 2025, to review the proposal for the company's Q3 2025 report [1] - For the year 2024, Zhongwang Software's revenue composition is 99.86% from the software industry and 0.14% from other businesses [1] - As of the report date, Zhongwang Software has a market capitalization of 13.4 billion yuan [1] Group 2 - The article highlights that China's innovative pharmaceuticals have generated $80 billion in overseas licensing deals this year [1] - It discusses the current hot market in the secondary sector of biomedicine while noting that fundraising in the primary market is facing challenges [1]

每经头条（nbdtoutiao）——中国创新药，今年海外授权已卖出800亿美元！对话创东方投资合伙人卢 刚：生物医药二级市场火热，一级市场为何募资遇冷？ （记者 王晓波） 每经AI快讯，中望软件（SH 688083，收盘价：79.16元）10月24日晚间发布三季度业绩公告称，2025年 前三季度营收约5.38亿元，同比增加4.99%；归属于上市公司股东的净利润亏损约4085万元；基本每股 收益亏损0.24元。 截至发稿，中望软件市值为134亿元。 ...

证券代码：688083 证券简称：中望软件 公告编号：2025-067 3、2023 年 9 月 26 日至 2023 年 10 月 5 日，公司对本激励计划拟授予激励 对象的姓名和职务在公司内部进行了公示。在公示期内，公司监事会未收到任何 人对本次拟激励对象名单提出的异议。2023 年 10 月 13 日，公司于上海证券交 易所网站（www.sse.com.cn）披露了《监事会关于公司 2023 年限制性股票激励 计划激励对象名单的公示情况说明及核查意见》（公告编号：2023-054）。 4、2023 年 10 月 17 日，公司召开 2023 年第三次临时股东大会，审议并通 过了《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2023 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提请 股东大会授权董事会办理公司 2023 年限制性股票激励计划相关事项的议案》。 2023 年 10 月 18 日，公司于上海证券交易所网站（www.sse.com.cn）披露《关于 公司 2023 年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况 的自查报告》（公告编号 ...